Table 2.

Association between the endogenous DNA damage level and patients’ clinicopathological characteristics using univariate statistical analysis (N = 74; a cutoff value of 6.34 was used for dichotomization of endogenous DNA damage level measured in the patients’ PBMCs).

		The DNA Damage Level ≤6.34 >6.34
Variable	N	%	N	%	p Value b
All patients	55	74.3	19	25.7	NA
Histology
Seminoma	13	65.0	7	35.0	0.37
Nonseminoma	42	77.8	12	22.2
Tumor primary
Primary GCTs	54	76.1	17	23.9	0.16
Extragonadal GCTs	1	33.3	2	66.7
IGCCCG risk group
Good risk + adjuvant therapy	32	74.4	11	25.6	0.54
Intermediate + poor risk	2	28.6	5	71.4
No. of metastatic site(s)
0	14	77.8	4	22.2	0.11
1 to 2	35	79.5	9	20.5
>3	6	50.0	6	50.0
Retroperitoneal lymph node metastases
Absent	17	81.0	4	19.0	0.56
Present	38	71.7	15	28.3
Mediastinal lymph node metastases
Absent	50	78.1	14	21.9	0.11
Present	5	50.0	5	50.0
Lung metastases
Absent	46	76.7	14	23.3	0.33
Present	9	64.3	5	35.7
Liver metastases
Absent	50	73.5	18	26.5	1.00
Present	5	83.3	1	16.7
Non-pulmonary visceral metastases
Absent	48	72.7	18	27.3	0.67
Present	7	87.5	1	12.5
S stage a
0	21	80.8	5	19.2	0.61
1	19	76.0	6	24.0
2	8	61.5	5	38.5
3	7	70.0	3	30.0

SEM, standard error of the mean; IGCCCG, International Germ Cell Consensus Classification Group. Values of p ≤ 0.05 are considered statistically significant. ^a Defined by the IGCCCG criteria: S0, within normal limits; S1, AFP < 1000 ng/mL and/or β-HCG < 5000 mIU/mL and/or LDH < 1.5 U/L upper normal limit; S2, AFP 1000–10,000 ng/mL and/or β-HCG 5000–50,000 mIU/mL and/or LDH 1.5–10 U/L upper normal limit; S3, AFP > 10,000 ng/mL and/or β-HCG > 50,000 IU/mL and/or LDH > 10 U/L upper normal limit. ^b Univariate analysis.